[
  {
    "ts": "2025-11-03T18:20:43+00:00",
    "headline": "Why Moderna (MRNA) Stock Is Falling Today",
    "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing concerns about its financial performance and a recent clinical setback overshadowed an announcement about a new, early-stage study.",
    "url": "https://finance.yahoo.com/news/why-moderna-mrna-stock-falling-182043989.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "fa1fac2b-9f2f-3df3-af7b-58a244fdb2b5",
      "content": {
        "id": "fa1fac2b-9f2f-3df3-af7b-58a244fdb2b5",
        "contentType": "STORY",
        "title": "Why Moderna (MRNA) Stock Is Falling Today",
        "description": "",
        "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing concerns about its financial performance and a recent clinical setback overshadowed an announcement about a new, early-stage study.",
        "pubDate": "2025-11-03T18:20:43Z",
        "displayTime": "2025-11-03T18:20:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/7ed68d581c33e574792b9fa0fe3f670c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "MRNA Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xFZGGzZnWM6N6sCUARtq9w--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/7ed68d581c33e574792b9fa0fe3f670c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aiku5oDkVhvbobAoAonIcg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/7ed68d581c33e574792b9fa0fe3f670c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-moderna-mrna-stock-falling-182043989.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-moderna-mrna-stock-falling-182043989.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T12:00:00+00:00",
    "headline": "Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma",
    "summary": "CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational mRNA-based T-cell engager (TCE) for participants ...",
    "url": "https://finance.yahoo.com/news/moderna-announces-first-patient-dosed-120000242.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "063787c3-c683-3d02-853c-04ccf99d3551",
      "content": {
        "id": "063787c3-c683-3d02-853c-04ccf99d3551",
        "contentType": "STORY",
        "title": "Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma",
        "description": "",
        "summary": "CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational mRNA-based T-cell engager (TCE) for participants ...",
        "pubDate": "2025-11-03T12:00:00Z",
        "displayTime": "2025-11-03T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "<![CDATA[CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has ...]]>",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y14NrymWnVHtLPxT5mPm5g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dSewxxG3XkMHQTa3gmVr6w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-announces-first-patient-dosed-120000242.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-announces-first-patient-dosed-120000242.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T10:00:00+00:00",
    "headline": "Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark",
    "summary": "George Tidmarsh’s short run directing the agency’s principal drug review office reportedly ended in controversy. Elsewhere, Moderna advanced a T-cell engager and Lilly expanded a production push for its GLP-1 pill.",
    "url": "https://www.biopharmadive.com/news/tidmarsh-resigns-from-cder-kenvue-to-sell-to-kimberly-clark/804473/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "19e79e3e-1e46-3530-a404-76b5f0daa014",
      "content": {
        "id": "19e79e3e-1e46-3530-a404-76b5f0daa014",
        "contentType": "STORY",
        "title": "Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark",
        "description": "",
        "summary": "George Tidmarsh’s short run directing the agency’s principal drug review office reportedly ended in controversy. Elsewhere, Moderna advanced a T-cell engager and Lilly expanded a production push for its GLP-1 pill.",
        "pubDate": "2025-11-03T10:00:00Z",
        "displayTime": "2025-11-03T10:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/tidmarsh-resigns-from-cder-kenvue-to-sell-to-kimberly-clark/804473/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tidmarsh-resigns-cder-kenvue-sell-100000482.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AUPH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]